ASWAL ASSOCIATES- Intellectual Property Law firm India

  Critical Analysis: Intra-Cellular Therapies, Inc. v. Controller of Patents (2026:DHC:5394) C.A.(COMM.IPD-PAT) 24/2023 | Delhi High Court | Decided: 06.07.2026 I. Doctrinal Analysis: Novelty and the "Coverage vs. Disclosure" Question A. The genus-species anticipation problem The core novelty dispute was a classic Markush-genus-versus-species-selection issue. The appellant argued that arriving at the claimed species from the generic Formula I of D1/D7 required " multiple selections " among independent variables (R1–R6), and that the Controller impermissibly relied on more than one prior art document to construct a single "closest prior art" novelty attack — a submission with real doctrinal pedigree, since novelty (unlike obviousness) is ordinarily tested against a single prior document read as a whole. The Court's response — invoking AstraZeneca AB and Boehringer Ingelheim v. Vee Excel — collapses the " covered vs. disclosed " dist...

  I. Overview and Procedural Posture The Delhi High Court, in an appeal under Section 117A of the Patents Act, 1970, upheld the Controller's rejection (order dated 27.04.2023) of the patent application (No. 201817033732) titled "Organic Compounds" and covering deuterated heterocycle-fused gamma-carboline compounds (Formulas I–IV). The claims fell into two clusters: Claims 1–3 & 5–10 (Formula I–III compounds) and Claims 4 & 5–7 (Formula IV compounds), with Claim 11 as a dependent pharmaceutical composition claim. The claimed invention was for the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signalling systems and also has application in the treatment of diseases/disorders like anxiety, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, etc. The rejection rested on lack of novelty (Section 2(1)(j)), obviousness (Section 2(1)(ja)), and non-patentability under Sect...